Adequacy of endobronchial ultrasound‑guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma

Jeyabalan,Abiramy; Bhatt,Nidhi; Plummeridge,Martin J.; Medford,Andrew   R.L.

doi:10.3892/mco.2015.672

Adequacy of endobronchial ultrasound‑guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma

Authors:
- Abiramy Jeyabalan
- Nidhi Bhatt
- Martin J. Plummeridge
- Andrew R.L. Medford
View Affiliations

Affiliations: North Bristol Lung Centre and University of Bristol, North Bristol NHS Trust, Southmead Hospital, Bristol BS10 5NB, UK, Department of Pathology, University Hospitals Bristol NHS Trust, Bristol Royal Infirmary, Bristol BS2 8HW, UK
Published online on: November 9, 2015 https://doi.org/10.3892/mco.2015.672
Pages: 119-125

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phenotyping non‑small‑cell lung cancer is becoming increasingly important with the advent of molecular testing. Tumours harbouring somatic mutations in the gene that encodes for the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have been found to increase responsiveness to tyrosine kinase inhibitors. Endobronchial ultrasound‑guided transbronchial needle aspiration (EBUS‑TBNA) is a minimally invasive technique for mediastinal node sampling. The available prospective data on EBUS‑TBNA sample suitability for molecular profiling are currently limited. The aim of this prospective study was to evaluate the adequacy of EBUS‑TBNA samples for EGFR and anaplastic lymphoma kinase (ALK) genetic mutation analysis in confirmed primary lung adenocarcinomas. We conducted a prospective analysis of 410 consecutive patients referred for EBUS‑TBNA between 2010 and 2014. Rapid on‑site cytological evaluation was not used. The samples were obtained using 21‑gauge (21G) or 22G needles and were prepared as histopathological samples. A total of 91 samples were confirmed as lung adenocarcinomas and 80 of these samples were sent for EGFR mutation analysis. EBUS‑TBNA had a diagnostic accuracy of 98.3% for malignancy. EGFR mutation testing was possible in 79/80 cases (98.75%). EGFR mutations were detected in 5/80 (6.3%) samples. ALK gene analysis, which became available during the study period, was requested and successfully performed in 21̸21 samples (100%). The total combined genotyping success rate was 100/101 (99.0%). This UK study confirmed the high clinical utility of EBUS‑TBNA samples processed as histopathological specimens for EGFR and ALK genotyping in primary lung adenocarcinoma. The needle gauge did not affect genotyping efficacy.

View Figures

View References

1	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
2	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar : PubMed/NCBI
4	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
5	Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
6	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
7	National Institute for Health and Care Excellence: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer. http://publications.nice.org.uk/erlotinib-for-the-first-line-treatment-of-locally-advanced-or-metastatic-egfr-tk-mutation-positive-ta258Accessed. November 04–2013
8	National Institute for Health and Care Excellence: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene. http://www.nice.org.uk/guidance/TA296Accessed. August 29–2014
9	Medford AR, Bennett JA, Free CM and Agrawal S: Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med. 15:334–342. 2009. View Article : Google Scholar : PubMed/NCBI
10	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
11	Medford AR, Bennett JA, Free CM and Agrawal S: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): applications in chest disease. Respirology. 15:71–79. 2010. View Article : Google Scholar : PubMed/NCBI
12	Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, Spicer J, Breen R, McLean E and Tobal K: Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One. 6:e251912011. View Article : Google Scholar : PubMed/NCBI
13	Garcia-Olivé I, Monsó E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjós M, Castellà E, Moran T, Bertran-Alamillo J, et al: Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J. 35:391–395. 2010. View Article : Google Scholar : PubMed/NCBI
14	Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, Mohammed S, Miyagi Y, Matsukuma S, Sekine Y and Fujisawa T: Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 132:597–602. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nakajima T, Yasufuku K, Nakagawara A, Kimura H and Yoshino I: Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 140:1319–1324. 2011. View Article : Google Scholar : PubMed/NCBI
16	Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ and van der Heijden HF: A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol. 5:1664–1667. 2010. View Article : Google Scholar : PubMed/NCBI
17	Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, et al: Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol. 8:1438–1444. 2013. View Article : Google Scholar : PubMed/NCBI
18	Boulanger S, Delattre C, Descarpentries C, Escande F, Bouchindhomme B, Copin MC, Dhalluin X, Scherpereel A, Ramon PP, Cortot A, et al: Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration. Rev Mal Respir. 30:351–356. 2013.(In French). View Article : Google Scholar : PubMed/NCBI
19	Esterbrook G, Anathhanam S and Plant PK: Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. Lung Cancer. 80:30–34. 2013. View Article : Google Scholar : PubMed/NCBI
20	Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, Munavvar M, Ng BJ, Rassl DM, Falzon M, et al: Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med. 185:1316–1322. 2012. View Article : Google Scholar : PubMed/NCBI
21	Billah S, Stewart J, Staerkel G, Chen S, Gong Y and Guo M: EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 119:111–117. 2011. View Article : Google Scholar : PubMed/NCBI
22	Jurado J, Saqi A, Maxfield R, Newmark A, Lavelle M, Bacchetta M, Gorenstein L, Dovidio F, Ginsburg ME, Sonett J, et al: The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg. 96:1196–1202. 2013. View Article : Google Scholar : PubMed/NCBI
23	Yung RC, Otell S, Illei P, Clark DP, Feller-Kopman D, Yarmus L, Askin F, Gabrielson E and Li QK: Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer Cytopathol. 120:185–195. 2012. View Article : Google Scholar : PubMed/NCBI
24	Schmid-Bindert G, Wang Y, Jiang H, Sun H, Henzler T, Wang H, Pilz LR, Ren S and Zhou C: EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods. PLoS One. 8:e779482013. View Article : Google Scholar : PubMed/NCBI
25	Kang YR, Park HY, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YL, Han J, et al: EGFR and KRAS mutation analyses from specimens obtained by bronchoscopy and EBUS-TBNA. Thorac Cancer. 4:264–272. 2013. View Article : Google Scholar
26	Medford AR, Agrawal S, Free CM and Bennett JA: A performance and theoretical cost analysis of endobronchial ultrasound-guided transbronchial needle aspiration in a UK tertiary respiratory centre. QJM. 102:859–864. 2009. View Article : Google Scholar : PubMed/NCBI
27	Jeyabalan A, Shelley-Fraser G and Medford AR: Impact of needle gauge on characterization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) histology samples. Respirology. 19:735–739. 2014. View Article : Google Scholar : PubMed/NCBI
28	Medford AR and Pillai A: Cytotechnician rapid on-site evaluation for cytology for transbronchial needle aspiration. J Bronchology Interv Pulmonol. 20:189–190. 2013. View Article : Google Scholar : PubMed/NCBI
29	Travis WDI, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
30	Kaufmann O, Fietze E, Mengs J and Dietel M: Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 116:823–830. 2001. View Article : Google Scholar : PubMed/NCBI
31	Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P and Baloch Z: Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 37:178–183. 2009. View Article : Google Scholar : PubMed/NCBI
32	Yatabe Y, Mitsudomi T and Takahashi T: TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 26:767–773. 2002. View Article : Google Scholar : PubMed/NCBI
33	Stenhouse G, Fyfe N, King G, Chapman A and Kerr KM: Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 57:383–387. 2004. View Article : Google Scholar : PubMed/NCBI
34	Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162. 2014. View Article : Google Scholar : PubMed/NCBI
35	Diacon AH, Schuurmans MM, Theron J, Brundyn K, Louw M, Wright CA and Bolliger CT: Transbronchial needle aspirates: How many passes per target site? Eur Respir J. 29:112–116. 2007. View Article : Google Scholar : PubMed/NCBI
36	Yatabe Y, Matsuo K and Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 29:2972–2977. 2011. View Article : Google Scholar : PubMed/NCBI
37	Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
38	National Comprehensive Cancer Network: NCCN guidelines for patients. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed. March 20–2014
39	Jeyabalan A and Medford AR: Endobronchial ultrasound-guided transbronchial needle aspiration, patient satisfaction under light conscious sedation. Respiration. 88:244–250. 2014. View Article : Google Scholar : PubMed/NCBI
40	Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, Yoshino I, et al: EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin CancerRes. 16:4938–4945. 2010. View Article : Google Scholar